Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
Geoffrey R. Oxnard(Dana-Farber Cancer Institute), Pasi A. Jänne(Beth Israel Deaconess Medical Center), Neal I. Lindeman(Cornell University), Peter Lo(Harvard University), Bruce E. Johnson(Beth Israel Deaconess Medical Center), Mizuki Nishino(Brigham and Women's Hospital), Suzanne E. Dahlberg(Dana-Farber Cancer Institute), David M. Jackman(Brigham and Women's Hospital), Mohit Butaney(Brigham and Women's Hospital)
Cited by 358
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k